Show simple item record

dc.contributor.authorBerdeaux, Gilles
dc.contributor.authorLe Pen, Claude
dc.contributor.authorDe Natale, Renato
dc.date.accessioned2012-09-12T12:13:24Z
dc.date.available2012-09-12T12:13:24Z
dc.date.issued2011-04
dc.identifier.urihttps://basepub.dauphine.fr/handle/123456789/9972
dc.language.isoenen
dc.subjectHealth care regulationsen
dc.subject.ddc334en
dc.subject.classificationjelI12en
dc.titleEfficiency of Glaucoma Drug Regulation in 5 European Countries: A 1995-2006 Longitudinal Prescription Analysisen
dc.typeArticle accepté pour publication ou publié
dc.description.abstractenPurpose: To compare the evolution of prostaglandin analog (PGA) and β-blocker (BB) prescriptions across 5 European countries. Methods: Data were extracted from various sources: (1) IMS data for France, Germany, Italy, Spain, and the United Kingdom, (2) glaucoma-treated patients from the United Kingdom General Practice Research Database (UK-GPRD), (3) prescriptions delivered by the territorial pharmaceutical service of Monselice of the Padova region (Italy). Drugs were grouped into 3 classes: PGAs, BBs, and other drugs. Yearly market shares were calculated. Treatment persistence survival curves were estimated for Italian and UK data, and the 3 drug groups were compared using the Cochran Mantel Haenszel test. Results: According to Padova data, BBs decreased in market share, whereas PGAs increased. A linear extrapolation of these market shares, based on 1998 to 2003 data, predicted that the 2 curves should cross in 2005, a prediction reinforced by the European Medicines Agency authorization (2002) of PGAs as first-line glaucoma treatments. That this did not occur may be explained by Italy's refusal to reimburse PGAs as first-line therapy. IMS data identified Italy and Germany as 2 countries in which BBs are still more frequently prescribed than PGAs. Treatment persistence with PGAs as monotherapy, in PGA-naive patients, was longer than for BBs according to both Padova and UK-GPRD data. This held true for both first-line and second-line PGA prescriptions (UK-GPRD); the persistence of second-line PGA equalled first-line BB treatment. Conclusion: Health care regulations impacted upon glaucoma prescribing and may be one of the reasons for different annual evolution rates of PGA and BB prescriptions.en
dc.relation.isversionofjnlnameJournal of Glaucoma
dc.relation.isversionofjnlvol20en
dc.relation.isversionofjnlissue4en
dc.relation.isversionofjnldate2011-04
dc.relation.isversionofjnlpages234–239en
dc.relation.isversionofdoihttp://dx.doi.org/10.1097/IJG.0b013e3181e0791cen
dc.relation.isversionofjnlpublisherLippincotten
dc.subject.ddclabelEconomie socialeen
dc.relation.forthcomingnonen
dc.relation.forthcomingprintnonen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record